Alexey N Boyko

Alexey N Boyko

Auto-generated profile, based on publicly available information

Alexey N Boyko

Pirogov Russian National Research Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Degenerative Neurological and Neuromuscular Disease
Verified
Journal Article
Open access
ABAlexey Boyko
Alexey Boyko
OBOlga Boyko
Olga Boyko
Multiple sclerosis (MS) is one of the most important, disabling, and prevalent neurological disorders of young adults. It is a chronic inflammatory and neurodegenerative disease when autoreactive B and T cells have downstream effects that result in demyelination and neuronal loss. Anti-inflammatory disease-modifying therapies do have proven efficacy in delaying disease and disability progression in MS. While the progress in MS treatments has already improved the prognosis and quality of patients' lives overall, there are some clear shortcomings and unmet needs in the current MS treatment landscape. The most promising means of MS treatment is selective immune reconstitution therapy (SIRT). This therapy is given in short-duration courses of immunosuppression, producing durable effects on the immune system and preventing nervous tissue loss. This review discusses the mechanisms of action and the data of clinical trials of cladribine tablets as an example of SIRT in MS. The clinical benefits of cladribine tablets in these studies include decreased relapse rate and disability progression with large reductions in lesion activity, and protection against brain volume loss. Whether all of these neurological findings are direct results of lymphocyte depletion, or if there are downstream effects on other, unknown, neurodegenerative processes are yet to be determined, but these clearly point to an interesting area of research.

21 November 2012 in Pharmacogenomics
Verified
Journal Article
Closed access
OKOlga G Kulakova
Olga G Kulakova
ETEkaterina Yu Tsareva
Ekaterina Yu Tsareva
ABAlexey N Boyko
Alexey N Boyko
SSSergey G Shchur
Sergey G Shchur
EGEvgeny I Gusev
Evgeny I Gusev
OFOlga Favorova
Olga Favorova
IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software. Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy. The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them.

1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Open access
PDF file
ABA N Boyko
A N Boyko
NLN Yu Lashch
N Yu Lashch
SSS N Sharanova
S N Sharanova
MZM N Zakharova
M N Zakharova
OTO V Trifonova
O V Trifonova
MSM S Shustova
M S Shustova
Medical article медицинская статья

10 February 2010 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
ABAlexey N Boyko
Alexey N Boyko
Importance of the field: High-dose, high-frequency IFN β-1a in multiple sclerosis (MS) can prevent lesion formation, decrease the frequency/severity of relapses and delay progression of disability, with a proven safety profile. Rates of non-adherence are high. There are drugs under investigation that may have greater efficacy and different safety profiles from existing therapies. Areas covered in this review: Evidence supporting the efficacy of IFN β-1a, factors contributing to non-adherence, and strategies to combat non-adherence. It is hoped that these strategies, coupled with future advances in pharmacogenetics, might lead to better outcomes. The PubMed database was searched using the terms “multiple sclerosis” and “interferon beta-1a”, for papers published between 1998 and 2010. Relevant manuscripts and pivotal papers from clinical trials were cited. Searches of abstracts from congresses were also performed to obtain recent findings. What the reader will gain: An overview of early pivotal trials, comparative studies with other treatments, and recent studies assessing the development of this therapy. Take home message: Long-term treatment with IFN β-1a has benefits in MS and a good safety profile. Although adherence outside of clinical trials can be poor, injection devices, better tolerated drug formulations and education regarding treatment expectations are some of the strategies employed to help patients to adhere to treatment in the hope of improving outcomes.

1 January 2018 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Open access
PDF file
NKN V Khachanova
N V Khachanova
KBK Z Bakhtiyarova
K Z Bakhtiyarova
ABA N Boyko
A N Boyko
YVYa V Vlasov
Ya V Vlasov
MDM V Davydovskaia
M V Davydovskaia
FKF A Khabirov
F A Khabirov
Medical article медицинская статья

15 December 2013 in Acta Naturae
Verified
Journal Article
Open access
PDF file
YLYakov Lomakin
Yakov Lomakin
MZM Yu Zakharova
M Yu Zakharova
ABAlexey Belogurov
Alexey Belogurov
NBN A Bykova
N A Bykova
MDM A Dronina
M A Dronina
AGAlexander Gabibov
Alexander Gabibov
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system that primarily affects young and middle-aged people. It is widely accepted that B lymphocyte activation is required for MS progression. Despite the fact that the exact triggering mechanisms of MS remain enigmatic, one may suggest that MS can be induced by viral or bacterial infection in combination with specific genetic and environmental factors. Using deep sequencing and functional selection methodologies we characterized clones of poly- and cross-reactive antibodies that are capable of simultaneous recognition of viral proteins and autoantigens. The latter, in turn, possibly may trigger MS progression through molecular mimicry. It was identified that two cross-reactive antigens are probably recognized by light or heavy chains individually. According to the high structural homology between selected autoantibodies and a number of various antiviral IgGs, we suggest that a wide range of pathogens, instead of a single virus, be regarded as possible triggers of MS.